MedWatch

Ambu's new duodenoscope reaches over 98 percent success rate

Clinical testing of Ambu's improved duodenoscope, the Ascope Duodeno 1.5, continues to yield promising results, the medtech company reports on Monday.

Photo: PR / Ambu

Ambu has once again obtained positive results from clinical testing of its improved single-use duodenoscope, the Ascope Duodeno 1.5, it reports in a press release.

In connection with Ambu's results from the finanical year 2020/2021, which were announced in early November, the medtech company announced that 29 people had tested the Ascope Duodeno 1.5, with a success rate of 100 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs